Forescout Expands Channel Program with New Managed Service Provider Partner Offering
14.6.2022 13:00:00 EEST | Business Wire | Press release
Forescout Technologies, the leader in automated cybersecurity, today announced the expansion of its Envision Channel Program, launching a new Managed Service Provider (MSP) Partner Program to support customers with enhanced technical and professional service capabilities.
Designed to offer Forescout’s most experienced and technically competent partners new flexible licensing options, consumption billing, and specialized resources, the MSP program expansion improves the partner-owned customer deployment and support experience. Forescout Partners, such as BT and Accenture, were instrumental in driving program enhancements to meet the increasing security challenges of their global customers.
Kevin Brown, Managing Director, Security for BT, said: “Cybersecurity is top of mind for our customers, who all want to ensure they’ve got the best protections for their most critical assets. BT has partnered with Forescout for several years, and we have more than 50 Forescout-accredited technical professionals supporting customer deployments around the world. This new program enhancement aligns with our customers’ demand for faster, more integrated solutions that tackle the changing threat landscape and enable their opportunities.”
“Forescout’s channel program has played a pivotal role in our company’s business journey. Our channel partners have helped countless enterprises around the globe obtain more visibility of their cyber assets to quickly mitigate critical risks,” said Keith Weatherford, vice president of worldwide channel sales, Forescout. “The evolving digital terrain is creating new demand to activate Forescout services and capabilities so these new initiatives will provide a seamless set of training and enablement resources to support them on this path.”
“We see this program as a great extension of the value we have been delivering to clients in partnership with Forescout,” said Jamie Bass, Managing Director, Security, Accenture. “Allowing an organization to more easily leverage Forescout’s industry leading capabilities in network visibility as a service supported by our global delivery team reduces the requirement to hire and train an organization’s own team to deploy and run the solution.”
The Forescout Envision Channel Program now encompasses:
- Managed Services and Service Delivery Partner Program: Exclusively for partners who have demonstrated a high level of technical expertise and proficiency when deploying and supporting the Forescout platform. It provides highly qualified partners with flexible licensing and billing options in exchange for owning the customer support experience
- Updated Partner Portal and New Forescout Academy Platform: Quick access to digitally rich learning resources and assets to demonstrate and be recognized for technical competencies across the Forescout platform and broad set of capabilities.
- Partner Learning Journey Expansion: As part of the new direction for the Envision Channel Program, Forescout has developed an Accredited Engineer course for technical partner staff to be introduced to the Forescout Continuum Platform. Additionally, it has created the Forescout Forerunner Program which recognizes partners who accelerate onboarding and service delivery for client end-users.
With its new accreditations for partner engineer and technical support and new Managed Service Program, Forescout is recognizing and rewarding its global partner ecosystem to drive new earning opportunities and recognize the value add that they bring to the company’s success.
To learn more about Forescout’s Envision Channel Program, visit: https://www.forescout.com/resources/managed-service-provider-partner-program-overview/
About Forescout
Forescout Technologies, Inc. delivers cybersecurity automation across the digital terrain, maintaining continuous alignment of customers’ security frameworks with their digital realities, including all asset types. The Forescout Continuum Platform provides 100% asset visibility, continuous compliance, network segmentation and a strong foundation for Zero Trust. For more than 20 years, Fortune 100 organizations and government agencies have trusted Forescout to provide automated cybersecurity at scale. Forescout arms customers with data-powered intelligence to accurately detect risks and quickly remediate cyberthreats without disruption of critical business assets. www.forescout.com
Managing cyber risk, together.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220614005091/en/
Contact information
Rebecca Cradick
Director of PR
rebecca.cradick@forescout.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release
Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom